2021
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljkovic M, Horvath TL, Hajós M. Therapy for Alzheimer’s disease: Missing targets and functional markers? Ageing Research Reviews 2021, 68: 101318. PMID: 33711510, PMCID: PMC8131215, DOI: 10.1016/j.arr.2021.101318.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseNew symptomatic treatmentsNeural network integrityClinical characteristicsNext-generation therapiesSymptomatic treatmentOutcome biomarkerTau pathologyFluid biomarkersPlasma biomarkersDisease progressionEffective therapyNeurophysiological biomarkersTreatment candidatesCerebrospinal fluidNovel biomarkersTranslational studiesTreatment interventionsDiseaseTarget engagementTherapyBiomarkersCurrent conceptsMultiple biomarkersDrug targets
2016
Hippocampal network dynamics in response to α7 nACh receptors activation in amyloid-β overproducing transgenic mice
Stoiljkovic M, Kelley C, Hajós GP, Nagy D, Koenig G, Leventhal L, Hajós M. Hippocampal network dynamics in response to α7 nACh receptors activation in amyloid-β overproducing transgenic mice. Neurobiology Of Aging 2016, 45: 161-168. PMID: 27459936, DOI: 10.1016/j.neurobiolaging.2016.05.021.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseΑ7 nicotinic acetylcholine receptorEffect of α7Wild-type miceGamma oscillationsNicotinic acetylcholine receptorsHippocampal network dynamicsSymptomatic treatmentClinical findingsAD patientsSaline controlsProcognitive drugsΑ7 nAChRsTransgenic miceAcetylcholine receptorsReceptor activationCognitive functionHippocampal oscillationsMiceNeurophysiological impairmentsAgonistsPower of thetaΑ7AβSignificant differences